Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review.

American journal of hematology - 1 Jun 2025

Gagelmann Nico, Kröger Nicolaus

Abstract excerpt

Allogeneic hematopoietic stem-cell transplantation (HCT) remains the only potentially curative therapy for patients with myelodysplastic neoplasms (MDS) and myelofibrosis (MF) and is the standard care for eligible patients with higher-risk disease. Despite significant advancements, both diseases pose unique challenges due to their clinical and molecular heterogeneity, necessitating personalized approaches to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allografts
Share to CALR gene
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Neoplasm, Residual

Share to Primary Myelofibrosis

Share to Transplantation, Homologous

Source

Open in PubMed Open full text

Identifiers

PMID: 40079242
DOI: 10.1002/ajh.27660
PMCID: PMC12067163

Genes

CALR
JAK2
MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review.PMID 40079242Read ↗

The current and future role of stem cells in myelodysplastic syndrome therapies.Semantic proximity Read ↗

Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative NeoplasmsSemantic proximity Read ↗

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies.Semantic proximity Read ↗

Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.Semantic proximity Read ↗

Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.Semantic proximity Read ↗

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasmsSemantic proximity Read ↗

The Use of Flow Cytometry in Myelodysplastic Syndromes: A ReviewSemantic proximity Read ↗

Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.Semantic proximity Read ↗

Myelodysplastic Neoplasms (MDS): The Current and Future Treatment LandscapeSemantic proximity Read ↗

Advances in myelodysplastic/myeloproliferative neoplasms.Semantic proximity Read ↗

Epidemiology and Pathogenesis of Myelodysplastic Syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.